Exicure (XCUR)
Develops burixafor for stem-cell mobilization before autologous transplant.
Something off on this page? Send us feedback.
Develops burixafor, an investigational CXCR4 inhibitor for stem-cell mobilization before autologous transplant, with potential direct-sale and sublicensing revenue. Operations center on a single licensed clinical asset, supported by a small U.S. staff and Korean counterparties, while the former SNA platform provides only contingent royalty and license-fee rights.
Develops burixafor, a licensed CXCR4 inhibitor being studied to mobilize hematopoietic stem cells for collection before autologous transplant in multiple myeloma. The program may be commercialized directly after regulatory approval or sublicensed; exploratory work with Adbiotech also covers combinations in sickle-cell disease, acute myeloid leukemia and solid tumors.
Operates with a small U.S. corporate staff, a California GPCR USA subsidiary, and Korean technology and development counterparties. The legacy SNA research platform was sold, leaving a time-limited right to related royalties and license fees. Burixafor is investigational and must move through further development, regulatory approval, manufacturing and commercialization; its license carries royalties, milestone payments and sublicensing constraints.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.7M · Total debt $0 · Total assets $11.4M · Shareholders' equity $977.0K
- Revenue
- $0
- Operating income
- −$1.1M
- Net income
- −$1.1M
No dividends on record.
| Institutions17 holders · as of Mar 31, 2026 | 2.46% | 161.2K shares | |
| Insiders2 holders · as of Feb 19, 2026 | 1.13% | 74.0K shares | |
| Strategic holders3 holders · as of Jul 17, 2026 | 97.84% | 6.40M shares | |
| Adds to | 101.43% |
6.55M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 101.43%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
HiTron Systems Inc.Strategic | 50.92% | 3.33M | 13Dfiled Mar 26, 2025 ↗ |
Exicure HiTron Inc.Strategic10 percent owner | 33.95% | 2.22M | 13Dfiled Jul 17, 2026 ↗ |
DGP Co., Ltd.Strategic10 percent owner | 12.97% | 849,223 | Form 4filed Sep 16, 2024 ↗ |
Andy YooInsiderdirector, officer: Chief Restructuring Officer | 1.13% | 73,666 | Form 4filed Nov 26, 2024 ↗ |
Carlyle Group Inc.Institution | 0.86% | 56,328 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 21, 2026 | Exicure HiTron Inc. | 10 percent owner | −258,367 | $4.50 |
| Jan 16, 2026 | Exicure HiTron Inc. | 10 percent owner | −734,747 | $4.50 |
| Jan 7, 2026 | Exicure HiTron Inc. | 10 percent owner | −741,272 | $4.50 |
| Dec 8, 2025 | Sangsangin Investment & Securities Co., Ltd. | 10 percent owner | −433,332 | $8.71 |
- Sanofi (ADR)
Approved plerixafor alternative in myeloma stem-cell mobilization.
- BioLineRx (ADR)
Approved CXCR4 alternative in myeloma stem-cell mobilization.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Exicure | $1.36 | +3.40% | $8.2M | — | — | — | — |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| BioLineRx (ADR) | $2.66 | −3.62% | $11.9M | — | — | 8.7 | −3.3% |
| Median | 78.2 | — | 5.3 | +4.0% |